v3.26.1
Segment Information
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Information Segment Information
Zevra manages its business activities on a consolidated basis and operates as a single operating segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. The Company primarily derives its revenue from MIPLYFFA and OLPRUVA product sales and reimbursements received under the global EAP. For the six months ended June 30, 2026, and 2025, the Company's revenue included royalties generated under the AZSTARYS License Agreement.
Zevra's CODM is the Company's Chief Executive Officer, Neil F. McFarlane. The CODM uses net income, as reported in the Company's unaudited condensed consolidated statements of operations, in evaluating performance of its segment and determining how to allocate resources of the Company as a whole, including investing in its research and development, commercialization efforts, and acquisition strategy. The CODM does not review assets in evaluating the results of the segment, and, therefore, such information is not presented. The accounting policies of the segment are the same as those described in Note B.
The following table presents the operating results of the Company's segment for the three and six months ended June 30, 2026 and 2025 (in thousands):
Three months ended June 30,Six months ended June 30,
2026202520262025
Total revenues$39,663 $25,881 $75,883 $46,282 
Less significant segment expenses:
Research and development directly identified to programs2,206 2,339 5,138 4,700 
Research and development not directly identified to programs2,280 1,094 3,740 1,991 
Selling, general and administrative directly identified to programs3,132 6,439 9,564 14,000 
Selling, general and administrative not directly identified to programs13,427 14,343 27,778 26,327 
Other segment items:
Impairment of intangible assets— 58,710 — 58,710 
Income tax expense4,042 2,199 10,957 3,381 
Interest income(1,477)(2,257)(3,661)(2,975)
Depreciation and amortization expense316 1,651 732 3,300 
Interest expense— 2,009 1,711 3,978 
Other income, net (a)6,985 (135,353)(26,718)(138,738)
Segment net income$8,752 $74,707 $46,642 $71,608 
(a) Other income, net, included in segment net income includes the gain on sale of the PRV, cost of product revenue, intangible asset amortization, gain on sale of future royalties, intellectual property, and other assets, net, loss on extinguishment of debt, loss on derivative liability, fair value adjustment related to warrant and contingent value right (“CVR”) liabilities, fair value adjustments related to investments, and other overhead expenses.
The Company holds long-lived assets in the United States of $2.0 million and $2.2 million as of June 30, 2026, and December 31, 2025, respectively. The Company holds long-lived assets in Europe of $0.3 million and $0.4 million as of June 30, 2026, and December 31, 2025, respectively.